Antigenic peptide–MHC class II complex–T-cell receptor interface (pMHC II–TCR interface)

The **antigenic peptide–MHC class II complex–T-cell receptor interface** is the molecular structure formed when a T cell receptor (TCR) binds to a peptide antigen that is displayed by a major histocompatibility complex (MHC) class II molecule on an antigen-presenting cell. MHC class II molecules consist of an alpha and beta chain forming a peptide-binding groove, which presents peptides (typically 13–17 amino acids) derived from extracellular proteins to the TCR, predominantly activating CD4+ helper T cells[1][3][4][5]. The binding specificity and recognition at this interface underlie adaptive immune discrimination between self and nonself, and dysregulation of these interactions is linked to autoimmune diseases, cancer, and infectious disease pathogenesis[4][5][6]. Structural studies have revealed a diagonal docking geometry, with variability influenced by both the peptide sequence and the MHC polymorphisms, making it a structural and therapeutic target of interest for immunotherapy, vaccine design, and immune monitoring[2][6][7].

Other names

peptide/MHC class II–T-cell receptor interfacepeptide–MHC II–TCR interfacepMHC II–TCRpeptide–HLA class II–TCR interface

Bispecific TCR-mimetic therapeutics targeting specific peptide–MHC II complexes to redirect T cells against cancer[6] Cancer vaccines present defined peptide–MHC epitopes to drive helper T cell activation for immunotherapeutic effect[6] Indirect modulation of the interface via immune checkpoint inhibitors